{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Phylogenèse : Questions médicales les plus fréquentes",
"headline": "Phylogenèse : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Phylogenèse : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-29",
"dateModified": "2025-04-23",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Phylogenèse"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Sciences de l'information",
"url": "https://questionsmedicales.fr/mesh/D007254",
"about": {
"@type": "MedicalCondition",
"name": "Sciences de l'information",
"code": {
"@type": "MedicalCode",
"code": "D007254",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "L01"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Phylogenèse",
"alternateName": "Phylogeny",
"code": {
"@type": "MedicalCode",
"code": "D010802",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Josef Vlasák",
"url": "https://questionsmedicales.fr/author/Josef%20Vlas%C3%A1k",
"affiliation": {
"@type": "Organization",
"name": "Biology Centre, Czech Academy of Sciences, Institute of Plant Mol. Biol., Branišovská 31, CZ-370 05 České Budějovice, Czech Republic Biology Centre, Czech Academy of Sciences České Budějovice Czech Republic."
}
},
{
"@type": "Person",
"name": "Yu-Cheng Dai",
"url": "https://questionsmedicales.fr/author/Yu-Cheng%20Dai",
"affiliation": {
"@type": "Organization",
"name": "School of Ecology and Nature Conservation, Beijing Forestry University, Beijing 100083, China Beijing Forestry University Beijing China."
}
},
{
"@type": "Person",
"name": "Shu-Yan Liu",
"url": "https://questionsmedicales.fr/author/Shu-Yan%20Liu",
"affiliation": {
"@type": "Organization",
"name": "a Laboratory of Plant Pathology, College of Plant Protection, Jilin Agricultural University."
}
},
{
"@type": "Person",
"name": "Michael Bradshaw",
"url": "https://questionsmedicales.fr/author/Michael%20Bradshaw",
"affiliation": {
"@type": "Organization",
"name": "c Harvard University, Department of Organismic and Evolutionary Biology."
}
},
{
"@type": "Person",
"name": "Uwe Braun",
"url": "https://questionsmedicales.fr/author/Uwe%20Braun",
"affiliation": {
"@type": "Organization",
"name": "d Martin Luther University, Institute of Biology, Geobotany and Botanical Garden, Herbarium."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Methicillin-resistant Staphylococcus aureus-associated orbital cellulitis: a case series.",
"datePublished": "2023-04-07",
"url": "https://questionsmedicales.fr/article/37029211",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10792-023-02698-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mptx2 defends against peritoneal infection by methicillin-resistant staphylococcus aureus.",
"datePublished": "2022-05-21",
"url": "https://questionsmedicales.fr/article/35609377",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.intimp.2022.108856"
}
},
{
"@type": "ScholarlyArticle",
"name": "Predictors of Methicillin-resistant Staphylococcus aureus infection in children with acute osteomyelitis.",
"datePublished": "2024-10-10",
"url": "https://questionsmedicales.fr/article/39390563",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13052-024-01780-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Prevalence and risk factors for methicillin-resistant Staphylococcus aureus infection in children].",
"datePublished": "2024-01-22",
"url": "https://questionsmedicales.fr/article/38245868",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.37201/req/113.2023"
}
},
{
"@type": "ScholarlyArticle",
"name": "Vancomycin plus ceftaroline for persistent methicillin-resistant Staphylococcus aureus bacteremia.",
"datePublished": "2022-11-21",
"url": "https://questionsmedicales.fr/article/36371648",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/phar.2741"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Sciences de l'information",
"item": "https://questionsmedicales.fr/mesh/D007254"
},
{
"@type": "ListItem",
"position": 3,
"name": "Phylogenèse",
"item": "https://questionsmedicales.fr/mesh/D010802"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Phylogenèse - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Phylogenèse",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-11",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Phylogenèse",
"description": "Comment déterminer la phylogénie d'une espèce ?\nQuels outils sont utilisés en phylogénie ?\nQu'est-ce qu'un arbre phylogénétique ?\nQuelle est l'importance de la phylogénie ?\nComment la phylogénie aide-t-elle en médecine ?",
"url": "https://questionsmedicales.fr/mesh/D010802?mesh_terms=Methicillin-Resistant+Staphylococcus+aureus&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Phylogenèse",
"description": "Quels symptômes peuvent indiquer une évolution rapide ?\nComment les symptômes évolutifs se manifestent-ils ?\nLes symptômes peuvent-ils être liés à la phylogénie ?\nQuels symptômes sont observés chez les espèces en danger ?\nComment les symptômes évolutifs influencent-ils la survie ?",
"url": "https://questionsmedicales.fr/mesh/D010802?mesh_terms=Methicillin-Resistant+Staphylococcus+aureus&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Phylogenèse",
"description": "Comment la phylogénie contribue-t-elle à la prévention des maladies ?\nQuels rôles jouent les études phylogénétiques en santé publique ?\nComment prévenir la propagation des pathogènes ?\nLa phylogénie peut-elle aider à prévenir les zoonoses ?\nQuels sont les défis de la prévention basée sur la phylogénie ?",
"url": "https://questionsmedicales.fr/mesh/D010802?mesh_terms=Methicillin-Resistant+Staphylococcus+aureus&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Phylogenèse",
"description": "Comment la phylogénie influence-t-elle les traitements médicaux ?\nQuels traitements sont basés sur la phylogénie ?\nLa phylogénie aide-t-elle à la découverte de médicaments ?\nQuels sont les défis des traitements basés sur la phylogénie ?\nComment la phylogénie aide-t-elle à prévenir les résistances ?",
"url": "https://questionsmedicales.fr/mesh/D010802?mesh_terms=Methicillin-Resistant+Staphylococcus+aureus&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Phylogenèse",
"description": "Quelles complications peuvent survenir en cas d'évolution rapide ?\nComment la phylogénie aide-t-elle à comprendre les complications ?\nQuelles complications sont liées aux infections virales ?\nLes complications peuvent-elles être prédites par la phylogénie ?\nComment gérer les complications liées à la phylogénie ?",
"url": "https://questionsmedicales.fr/mesh/D010802?mesh_terms=Methicillin-Resistant+Staphylococcus+aureus&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Phylogenèse",
"description": "Quels facteurs de risque influencent l'évolution des pathogènes ?\nComment l'environnement affecte-t-il la phylogénie ?\nQuels comportements augmentent les risques d'infection ?\nLes voyages influencent-ils la phylogénie des maladies ?\nComment la biodiversité affecte-t-elle les risques de maladies ?",
"url": "https://questionsmedicales.fr/mesh/D010802?mesh_terms=Methicillin-Resistant+Staphylococcus+aureus&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment déterminer la phylogénie d'une espèce ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "On utilise des analyses génétiques et morphologiques pour établir des relations évolutives."
}
},
{
"@type": "Question",
"name": "Quels outils sont utilisés en phylogénie ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les outils incluent les arbres phylogénétiques et les logiciels de bioinformatique."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'un arbre phylogénétique ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est une représentation graphique des relations évolutives entre différentes espèces."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de la phylogénie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle aide à comprendre l'évolution des espèces et leur adaptation à l'environnement."
}
},
{
"@type": "Question",
"name": "Comment la phylogénie aide-t-elle en médecine ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle permet de tracer l'origine des pathogènes et d'identifier des cibles thérapeutiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer une évolution rapide ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des changements rapides dans les traits d'une population peuvent signaler une évolution."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évolutifs se manifestent-ils ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent se manifester par des variations morphologiques ou comportementales."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils être liés à la phylogénie ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains symptômes peuvent être hérités et refléter des relations évolutives."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont observés chez les espèces en danger ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes de stress, de déclin de la reproduction et de perte de diversité peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évolutifs influencent-ils la survie ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent affecter l'adaptation et la capacité de survie dans un environnement changeant."
}
},
{
"@type": "Question",
"name": "Comment la phylogénie contribue-t-elle à la prévention des maladies ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle aide à identifier les souches pathogènes et à développer des stratégies de vaccination."
}
},
{
"@type": "Question",
"name": "Quels rôles jouent les études phylogénétiques en santé publique ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent de surveiller les épidémies et de comprendre la transmission des maladies."
}
},
{
"@type": "Question",
"name": "Comment prévenir la propagation des pathogènes ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "En utilisant des données phylogénétiques pour cibler les interventions de santé publique."
}
},
{
"@type": "Question",
"name": "La phylogénie peut-elle aider à prévenir les zoonoses ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle permet d'identifier les espèces réservoirs et de réduire les risques de transmission."
}
},
{
"@type": "Question",
"name": "Quels sont les défis de la prévention basée sur la phylogénie ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les changements rapides des pathogènes peuvent compliquer les efforts de prévention."
}
},
{
"@type": "Question",
"name": "Comment la phylogénie influence-t-elle les traitements médicaux ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle permet de développer des traitements ciblés basés sur les relations évolutives des pathogènes."
}
},
{
"@type": "Question",
"name": "Quels traitements sont basés sur la phylogénie ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccins et les thérapies géniques peuvent être développés en tenant compte de la phylogénie."
}
},
{
"@type": "Question",
"name": "La phylogénie aide-t-elle à la découverte de médicaments ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle guide la recherche de nouvelles molécules en identifiant des cibles évolutives."
}
},
{
"@type": "Question",
"name": "Quels sont les défis des traitements basés sur la phylogénie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les variations génétiques rapides des pathogènes peuvent rendre les traitements moins efficaces."
}
},
{
"@type": "Question",
"name": "Comment la phylogénie aide-t-elle à prévenir les résistances ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle permet d'anticiper les mutations et d'adapter les traitements pour éviter les résistances."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir en cas d'évolution rapide ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des résistances aux traitements et des épidémies peuvent survenir en raison d'évolutions rapides."
}
},
{
"@type": "Question",
"name": "Comment la phylogénie aide-t-elle à comprendre les complications ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle permet d'analyser les relations entre les souches et les complications associées."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées aux infections virales ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les infections virales peuvent entraîner des complications respiratoires et neurologiques."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être prédites par la phylogénie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, en étudiant les relations évolutives, on peut prédire certaines complications potentielles."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à la phylogénie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surveillance continue et des ajustements de traitement sont essentiels pour gérer les complications."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque influencent l'évolution des pathogènes ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les mutations génétiques, l'environnement et les interactions hôtes-pathogènes sont cruciaux."
}
},
{
"@type": "Question",
"name": "Comment l'environnement affecte-t-il la phylogénie ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les changements environnementaux peuvent favoriser certaines adaptations et influencer l'évolution."
}
},
{
"@type": "Question",
"name": "Quels comportements augmentent les risques d'infection ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des comportements comme le non-respect des mesures d'hygiène et la surpopulation augmentent les risques."
}
},
{
"@type": "Question",
"name": "Les voyages influencent-ils la phylogénie des maladies ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les voyages facilitent la propagation des souches et augmentent le risque d'épidémies."
}
},
{
"@type": "Question",
"name": "Comment la biodiversité affecte-t-elle les risques de maladies ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une biodiversité élevée peut réduire les risques de maladies en limitant la transmission entre espèces."
}
}
]
}
]
}
In recent years, methicillin-resistant Staphylococcus aureus (MRSA) orbital cellulitis (OC) has drawn increasing clinical and public health concern. We present a case series of MRSA OC encountered at ...
A multi-centre retrospective case series investigating MRSA OC in Australia from 2013 to 2022. Patients of all ages were included....
Nine cases of culture-positive non-multi-resistant MRSA (nmMRSA) OC were identified at four tertiary institutions across Australia (7 male, 2 female). Mean age was 17.1 ± 16.7 years (range 13-days to ...
NMMRSA OC can follow an aggressive clinical course causing severe orbital and intracranial complications across a wide demographic. However, early recognition, initiation of targeted antibiotics and s...
Methicillin-resistant Staphylococcus aureus (MRSA) has an increasing prevalence of multi-drug resistance. There is an urgent need for developing novel approaches to combat MRSA infection. Mucosal pent...
This study aims to identify risk factors associated with Methicillin-resistant Staphylococcus aureus (MRSA) infection in children diagnosed with acute osteomyelitis (AO) and to elucidate the laborator...
We conducted a retrospective analysis involving 123 children with acute osteomyelitis treated at our hospital. Upon admission, we measured white blood cell (WBC) counts, C-reactive protein (CRP) level...
The MRSA group had a significantly higher average age compared to the non-MRSA group (P < 0.05). Notably, the incidence of suppurative arthritis was significantly lower in the MRSA group (P < 0.05). A...
In children newly admitted with acute osteomyelitis, a CRP level exceeding 73.23 µg/mL may indicate a high likelihood of MRSA infection. For children with AO who have been hospitalized for three days ...
The objectives of this work were to know the prevalence of methicillin-resistant S. aureus (MRSA) infections in the paediatric population of our health department, to describe the risk factors for inf...
A retrospective, descriptive and analytical study of infections produced by MRSA versus those produced by MSSA was carried out during the years 2014 to 2018. Risk factors for MRSA infection were studi...
162 patients with S. aureus infections were identified. Of these, 25 (15.4%) were MRSA. The highest percentages of MRSA infection occurred among children who required hospital admission (23.4%). In th...
Our results suggest the need to review empirical local treatment regimen using drugs active against MRSA in infections of probable staphylococcal origin admitted to the hospital, especially if they ha...
The preferred antibiotic salvage regimen for persistent methicillin-resistant Staphylococcus aureus bacteremia (MRSAB) is unclear. We sought to evaluate the effectiveness and safety of vancomycin plus...
Single-center, retrospective cohort study between January 1, 2016, and December 31, 2021....
State University of New York Upstate University Hospital, a 748-bed tertiary care, academic medical center in Syracuse, NY....
Adult patients were included if they had blood cultures positive for MRSA ≥72 h, received vancomycin monotherapy initially, and received vancomycin plus ceftaroline for ≥24 h. Patients were excluded i...
Patients were medically complex with a median Pitt bacteremia score of 3, 63.3% (19/30) were admitted to the intensive care unit, and 66.7% (20/30) had infective endocarditis. Vancomycin-associated ac...
Vancomycin plus ceftaroline may represent an effective and well-tolerated salvage regimen option for persistent MRSAB....
Staphylococcus aureus is a common germ in bacterial infections in children. The rate of methicillin-resistant S. aureus (MRSA) is increasing lately....
The main aim is to know the rate of positive cultures to MRSA in Spanish pediatric emergency departments. The secondary aims are to analyse the risk factors for MRSA isolation (patient origin, history...
Retrospective multicenter study (07/01/2017-06/30/2018) with review of patient histories with isolation of S. aureus in samples of any origin obtained in 8 pediatric emergency departments of the Infec...
During this period, S. aureus was detected in 403 patients (average age 75.8 ± 59.2 months; 54.8% male): 28.8% hospital-related infections (HRI) and 71.2% community-related infections (CRI). Overall, ...
The overall MRSA rate was one in 6 staphylococcal infections. Higher MRSA rates were detected in samples of suppurating skin injuries and in foreign children or in children with a history of previous ...
We aimed to determine the synergistic effects of ceftaroline (CPT) in combination with daptomycin (DAP), vancomycin (VAN), or linezolid (LNZ) against various methicillin-resistant Staphylococcus aureu...
MRSA strains randomly selected from 2014 to 2018 were studied. Checkerboard titration and in vitro time-kill analyses were used to determine the synergistic activities of the antibiotic combinations....
A total of 10 genetically distinct MRSA strains were included in this study. The checkerboard titration analysis revealed that the CPT-DAP, CPT-VAN, and CPT-LNZ combinations had a synergistic effect a...
The CPT-DAP combination showed better synergistic activity than the CPT-VAN and CPT-LNZ combinations against the enrolled MRSA strains. DAP, rather than VAN or LNZ, might be a better choice for CPT co...
The methicillin-resistant Staphylococcus aureus (MRSA) polymerase chain reaction (PCR) has a high negative predictive value (NPV). We aimed to understand if there was a difference in the NPV of the MR...
We performed a single-center, retrospective cohort study of adults with a positive respiratory culture and MRSA nasal PCR admitted to a surgical ICU from 2016 to 2019. Patients were stratified by surg...
We analyzed 61 patients: 42.6% (n = 26) ACS-ICU and 57.4% (n = 35) CVICU. There were no differences in age, comorbidities, prior MRSA infection, recent antibiotic use, immunocompromised status, or ren...
The MRSA nasal PCR screen has a high NPV for ruling out MRSA pneumonia in critically ill surgical patients. However, patients in the CVICU and patients hospitalized ≥5 d had a longer time to de-escala...
Severe infections of virulent methicillin-resistant Staphylococcus aureus (MRSA) are a serious health problem. The present study aimed to investigate clonal spread, virulence and antimicrobial resista...
Molecular identification and mecA gene detection were performed with PCR. Clonal relatedness was evaluated by RAPD PCR and MLST. MRSA epidemiology, virulence and resistance patterns were investigated ...
All 27 isolates were identified as S. aureus and were mecA positive, and all were susceptible to linezolid, tigecycline and vancomycin. The toxin genes hlg (in 92.6% of isolates), seb (77.8%), sei (77...
To the best of our knowledge, this study is the first describing the clonal spreading of Bulgarian MRSA and the association with their virulence and resistance determinants. Monitoring of MRSA epidemi...
Endoscopic endonasal approach (EEA) procedures are inherently contaminated due to direct access through the nasopharyngeal mucosa. The reported rate of postoperative meningitis in EEA procedures is 0....
All adult patients who underwent EEA resection at our institution from 2013 to 2021 were retrospectively reviewed. Patients with preoperative cerebrospinal fluid infections were excluded. Data includi...
Of 483 patients identified (mean age, 51 years; range, 18-90 years; 274 [56.7%] female), 80 (16.6%) had a positive preoperative methicillin-resistant Staphylococcus aureus (MRSA)/methicillin-sensitive...
Postoperative rates of meningitis after EEA surgery were not significantly changed based on MRSA/MSSA colonization status of the patient or preoperative decolonization. The utility of preoperative tes...